Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Opiant Pharmaceuticals announces plans for intranasal nalmefene

Feb. 13, 2018

V1B receptor antagonism may enhance alcohol dependency treatment

Feb. 6, 2018

Achieve Life Sciences amends technology license agreement with University of Bristol

Jan. 25, 2018

AP-202 shows promise as an agent for nicotine addiction

Jan. 23, 2018

FDA issues complete response letter for CAM-2038 NDA for opioid use disorder

Jan. 22, 2018

Mosedipimod receives FDA orphan drug designation for ARS

Jan. 5, 2018

Addex and Indivior sign licensing and collaboration agreement for ADX-71441 to treat addiction

Jan. 3, 2018

Axsome Therapeutics and Duke University to collaborate on phase II study of AXS-05

Dec. 15, 2017

FDA approves once-monthly Sublocade to treat opioid use disorder

Dec. 1, 2017

FDA accepts, grants priority review to lofexidine NDA

Nov. 22, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...